TP53 and diffuse large B-cell lymphoma: (76) demonstrated that IDO1 inhibition downregulates MDM2 expression in DLBCL cells, activates the p53 signaling pathway, and induces cell cycle arrest and apoptosis, ultimately improving patient outcomes.